Cargando…
Secretion of bispecific protein of anti-PD-1 fused with TGF-β trap enhances antitumor efficacy of CAR-T cell therapy
Despite the remarkable success of chimeric antigen receptor-modified T (CAR-T) cell therapy for blood malignancies, the clinical efficacy of this novel therapy in solid tumor treatment is largely limited by the immunosuppressive tumor microenvironment (TME). For instance, immune checkpoints (e.g., p...
Autores principales: | Chen, Xianhui, Yang, Shuai, Li, Si, Qu, Yun, Wang, Hsuan-Yao, Liu, Jiangyue, Dunn, Zachary S., Cinay, Gunce E., MacMullan, Melanie A., Hu, Fangheng, Zhang, Xiaoyang, Wang, Pin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082048/ https://www.ncbi.nlm.nih.gov/pubmed/33981830 http://dx.doi.org/10.1016/j.omto.2021.03.014 |
Ejemplares similares
-
Arming Anti-EGFRvIII CAR-T With TGFβ Trap Improves Antitumor Efficacy in Glioma Mouse Models
por: Li, You, et al.
Publicado: (2020) -
Quantitative Proteomics and Metabolomics Reveal Biomarkers of Disease as Potential Immunotherapy Targets and Indicators of Therapeutic Efficacy
por: MacMullan, Melanie A., et al.
Publicado: (2019) -
Bispecific GPC3/PD-1 CAR-T cells for the treatment of HCC
por: Li, Dezhi, et al.
Publicado: (2023) -
Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer
por: Yi, Ming, et al.
Publicado: (2022) -
Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity
por: Zhang, Congcong, et al.
Publicado: (2021)